AURKA rs2229523: What Your Genotype Means

What each genotype means

Understanding the rs2229523 Variant

The rs2229523 variant is a single nucleotide polymorphism (SNP) located in the AURKA gene on chromosome 20. Specifically, this variant results in a codon change at position 57, where the amino acid valine is replaced by isoleucine (Val57Ile). In genetics, SNPs represent the most common type of variation among people, where a single building block of DNA—a nucleotide—differs between individuals. Because this change occurs within the coding region of the gene, it has the potential to alter the structure or function of the resulting protein. Researchers track these variations to understand how they might influence biological processes, particularly those related to cell division and growth, which are often dysregulated in cancer. By studying where this variant sits within the gene, scientists can better investigate whether it acts as a marker for disease susceptibility or as a predictor for how a patient might respond to specific medical interventions.

The Role of the AURKA Gene

The AURKA gene provides instructions for making a protein called Aurora A kinase. This protein is a critical regulator of the cell cycle, specifically ensuring that cells divide correctly. During mitosis, or cell division, Aurora A kinase is found at the centrosomes and spindle poles, where it helps organize the machinery required to pull chromosomes apart into two new daughter cells. Beyond its role in mitosis, recent research has highlighted that AURKA can also function in the nucleus as a transcription factor, influencing the expression of genes that promote cell proliferation and survival. When the AURKA gene is overexpressed or mutated, it can lead to genomic instability, centrosome amplification, and uncontrolled cell growth. Because of these functions, AURKA has become a significant focus in oncology research, as it is frequently overexpressed in various malignancies, including breast, lung, and colorectal cancers, making it a target for therapeutic inhibitors.

Research and Clinical Associations

The evidence linking rs2229523 to clinical outcomes is considered moderate. Research has primarily focused on how this variant might influence the efficacy of Aurora A kinase inhibitors, such as alisertib, in patients with solid tumors. While AURKA overexpression is a known factor in cancer progression and resistance to certain treatments, the specific impact of the Val57Ile variant on drug response is still being characterized. Some studies suggest that genetic variations in AURKA may correlate with how well a patient responds to targeted therapy, but these findings are often derived from exploratory clinical trials rather than large-scale, definitive studies. It is important to note that cancer is a complex disease influenced by many genetic and environmental factors. Therefore, while this variant is a subject of interest in pharmacogenomics, it is not currently used as a standard diagnostic tool to dictate treatment plans. Any questions regarding how genetic information might relate to a specific treatment plan should be discussed with a qualified oncologist or pharmacist.

Population Frequency and Interpretation

The frequency of the rs2229523 variant is variable across different global populations. Genetic databases indicate that the distribution of the alleles can differ significantly depending on ancestral background. This variability is common for many human genetic variants and underscores the importance of considering population-specific data when interpreting genetic research. Because the frequency is not uniform, the potential impact of this variant may also be more or less relevant depending on the demographic group being studied. Researchers continue to collect data to better understand these frequency patterns and how they might influence the broader applicability of pharmacogenomic findings. For the general public, it is essential to recognize that having a particular genotype does not guarantee a specific health outcome or response to medication. Genetic information is only one piece of a much larger clinical puzzle that includes medical history, tumor characteristics, and other lifestyle factors.

What You Can Do With This Information

If you have received information about your rs2229523 genotype, it is important to view it within the context of your overall health. This variant is currently a subject of scientific research rather than a standard clinical test used for routine medical decision-making. You cannot use this information to diagnose yourself or to predict with certainty how you will respond to any medication. If you are currently undergoing treatment for cancer or are considering a clinical trial, the most appropriate step is to have an open conversation with your healthcare team. Your oncologist or a genetic counselor can help you understand the relevance of your genetic profile in the context of your specific diagnosis and treatment options. They are best equipped to interpret how emerging research, such as studies on AURKA inhibitors, might apply to your unique clinical situation. Always rely on professional medical advice rather than independent interpretation of genetic data.

Frequently asked questions

Sources & further reading